P-LAP/IRAP-induced cell proliferation and glucose uptake in endometrial carcinoma cells via insulin receptor signaling

BMC Cancer. 2007 Jan 19:7:15. doi: 10.1186/1471-2407-7-15.

Abstract

Background: Hyperglycemia or hyperinsulinemia contributes to poorer endometrial cancer survival. It was shown that P-LAP/IRAP translocates to the plasma membrane in response to insulin stimulation. Recently, we demonstrated that P-LAP/IRAP is associated with a poor prognosis in endometrial adenocarcinoma patients. The aim of this study was to examine whether the malignant potential of endometrial cancer enhanced by P-LAP/IRAP is due to increased glucose uptake via the P-LAP/IRAP-mediated activation of insulin signaling.

Methods: We transfected P-LAP/IRAP cDNA into A-MEC cells (endometrial adenocarcinoma cell line), and A-MEC-LAP cells expressed a remarkably high level of GLUT4 proteins.

Results: 3H-2-deoxyglucose uptake which responds to insulin in A-MEC-LAP cells was significantly higher than that of A-MEC-pc cells. A-MEC-LAP cells exhibited a significant growth-stimulatory effect compared to A-MEC-pc cells. A-MEC-LAP cells expressed a remarkably high level of p85PI3K protein compared to A-MEC-pc cells, and showed a higher degree of AKT phosphorylation by insulin stimulation.

Conclusion: In summary, P-LAP/IRAP was involved in the increasing malignant potential of endometrial cancer mediated by insulin. P-LAP/IRAP was suggested to be a potential new target of molecular-targeted therapy for endometrial cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analysis of Variance
  • Blotting, Western
  • Cell Line, Tumor
  • Cell Proliferation
  • Cystinyl Aminopeptidase / metabolism*
  • Endometrial Neoplasms / metabolism*
  • Endometrial Neoplasms / pathology*
  • Female
  • Glucose / pharmacokinetics*
  • Glucose Transporter Type 4 / metabolism*
  • Humans
  • Immunohistochemistry
  • In Vitro Techniques
  • Receptor, Insulin / metabolism*
  • Receptor, Insulin / physiology
  • Signal Transduction / drug effects
  • Transfection

Substances

  • Glucose Transporter Type 4
  • Receptor, Insulin
  • Cystinyl Aminopeptidase
  • leucyl-cystinyl aminopeptidase
  • Glucose